FOSUN PHARMA (02196) saw its shares rise more than 5% during the trading session. At the time of writing, the stock was up 3.84%, trading at HK$18.93, with a turnover of HK$249.407 million.

On the evening of March 24, FOSUN PHARMA released its 2025 annual results. The group reported revenue of RMB 41.662 billion, an increase of 1.45% year-on-year. Net profit attributable to shareholders of the listed company was RMB 3.371 billion, up 21.69% compared to the previous year. Basic earnings per share were RMB 1.27, and the company proposed a cash dividend of RMB 3.90 per 10 shares (pre-tax). Additionally, net cash flow from operating activities was RMB 5.213 billion, representing a 16.45% increase year-on-year.

During the reporting period, the group's revenue from innovative drugs reached RMB 9.893 billion, a growth of 29.59% year-on-year. This segment now accounts for 33.16% of the pharmaceutical business revenue, an increase of 6.77 percentage points from the previous year. Core products such as Peijin, Oukangze, and Yikaida all achieved growth rates exceeding 30%, while products including Hanlikang, Hanquyou, and Hansizhuang maintained steady revenue growth.